Clinical Development Presentation Protein Expression 
Drug Target Review
MAY 22, 2024
Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1
The Pharma Data
JUNE 7, 2023
Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. More than one million people are diagnosed with NSCLC at an advanced stage each year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 26, 2022
Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.
Conversations in Drug Development Trends
MAY 30, 2024
Differences in regulatory sentiments and industry sponsors’ subsequent clinical development strategies historically restricted access based on geography. The post Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies appeared first on Worldwide Clinical Trials.
The Pharma Data
MARCH 8, 2021
VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine.
The Pharma Data
JULY 21, 2021
Positive top-line results have already been reported for two Phase 2 clinical trials of VLA15 in over 800 healthy adults. VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. About VLA15.
The Pharma Data
SEPTEMBER 2, 2020
Other data to be presented will show high treatment persistence and strong adherence for patients treated with OCREVUS compared to other DMTs in real-world settings. A full list of Roche presentations can be found at: [link]. Presentations at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting include: Medicine. Abstract Title.
Expert insights. Personalized for you.
59 
Let's personalize your content